Business Of Biotech
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.
Episodes
265 episodes
Innovating On The Frontier Of Radiopharmaceuticals With RadioMedix's Ebrahim Delpassand, M.D.
On this week's episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing a radiopharmaceutical company focused on oncology. Dr. Delpassand discusses t...
•
Episode 264
•
54:07
Building An Efficient Biopharma With South Rampart Pharma's Hernan Bazan, M.D.
On this week's episode, Dr. Hernan Bazan, M.D., co-founder and CEO at New Orleans-based South Rampart Pharma, talks about building an ultra-lean drug development company to address an unmet need observed in his own patients as a surgeon: safe t...
•
Episode 263
•
45:41
The Business And Science Of Obesity With Roger Cone, Ph.D., Founder Of Courage Therapeutics
On this week's episode, Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, how he spun his academic discoveries out into a biote...
•
Episode 262
•
54:23
BoB Live At BIO: Amber Salzman, Ph.D., Epicrispr Biotechnologies
This week's episode is one from the road, recorded in front of a live audience in Boston's Seaport neighborhood during the BIO conference (special thanks to MasterControl for making it happen). Amber Salzman, Ph.D., CEO of Epicrispr Biotechnolo...
•
Episode 261
•
32:56
How To Be A Policy Advocate For Biotech With NewYorkBIO's Jennifer Hawks Bland
On this week's episode of the Business of Biotech, Jennifer Hawks Bland, CEO of NewYorkBIO, shares insights on New York State's life sciences ecosystem while reflecting on her journey from Capitol Hill to biotech advocacy. Her experiences in po...
•
Episode 260
•
56:34
FDA Trials And Tribulations With Connect Biopharma's Barry Quart
On this week's episode, Barry Quart, CEO of Connect Biopharma, weighs in on the current state of engagement between drug developers and the FDA, and how that key relationship continues to evolve under new leadership. Barry also discusses moving...
•
Episode 259
•
1:04:33
Proactive Procurement Strategies For Biotech With Tom Wells
On this week's episode of the Business of Biotech, Tom Wells, Director of Life Sciences at 4C Associates, reveals why -- and how -- smart procurement practices can make or break emerging biotech companies during critical growth stages. Tom shar...
•
Episode 258
•
58:23
The Discovery Of Microbes And Implications For Public Health Today, With Science Writer Thomas Levenson
On this week's episode, Thomas Levenson, MIT professor and author of So Very Small: How Humans Discovered The Microcosmos, Defeated Germs — And May Still Lose The War Against Infectious Disease talks about what...
•
Episode 257
•
1:06:27
Psychedelics For Mental Health Disorders With atai's Srinivas Rao, M.D., Ph.D.
On this week's episode, Dr. Srinivas Rao, co-founder and CEO at atai Life Sciences, explains how his engineering background led him to the development of psychedelic compounds for treating depression, anxiety, and other mental health disorders....
•
Episode 256
•
55:50
Biotech Angel Investing With Yaniv Sneor
On this week's episode, Yaniv Sneor, founder of the Mid Atlantic Bio Angels and CEO at Native State Therapeutics, explains how life science angel investors evaluate biotech startups, and offers tips for young drug developers in search of fundin...
•
Episode 255
•
56:27
Leading A tRNA Startup With Alltrna's Michelle Werner
On this week's episode, Michelle Werner, CEO at Alltrna, talks transfer RNA (tRNA) therapy with host Ben Comer and guest co-host Anna Rose Welch, editorial and community director at Advancing RNA. Wer...
•
Episode 254
•
59:23
Executing A Product Pivot With Vir Bio's Mark Eisner, MD
On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Bio, talks about the company's post-COVID pivot into infectious diseases (Hepatitis Delta and Hepatitis B) and oncology (solid tumors), how...
•
Episode 253
•
39:45
Commercializing RNAi Therapies With Alnylam's Tolga Tanguler
On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, the company's use of value-based contracts, a...
•
Episode 252
•
55:54
Big Pharma Insights For Building Biotech Startups With Uniquity Bio's Brian Lortie
On today's episode I'm speaking with Brian Lortie, President and CEO of Uniquity Bio, about his "no jerk" policy and how his experience building teams at GSK, Endo Pharmaceuticals, and Onspira Therapeutics informs his leadership at Uniquity, a ...
•
Episode 251
•
55:45
The Implications Of China's Growing Biotech Industry With Allan Shaw
Business of Biotech MVP Allan Shaw is back to talk about the rise of China's biotech sector, and its evolution from fast follower to global innovation powerhouse. Increased deal activity with Chinese biopharmaceutical companies is injecting new...
•
Episode 250
•
46:08
How To Be A CFO With Insmed's Sara Bonstein
On today's episode we're speaking with Sara Bonstein, Chief Financial Officer at Insmed, about what it takes to be a successful CFO. Sara provides useful insights on how to lead teams, especially when those teams have deeper subject matter expe...
•
Episode 249
•
44:20
Deal And Investment Trends With Investment Banker David Sans
Today we're talking life sciences investment trends and risks with David Sans, an investment banker with an academic background in chemical engineering and molecular modeling, and a professional background that began in Big Pharma and shifted t...
•
Episode 248
•
46:43
Business of Biotech 2.0 with Ben Comer
After nearly five years as host of the Business of Biotech podcast, Matt Pillar is handing the mic over to the voice of the Business of Biotech 2.0, veteran life sciences journalist Ben Comer. On this epsiode, Ben shares his nearly 20-year jour...
•
34:44
BoB@JPM: Nima Farzan, Latigo Biotherapeutics
In this final installment of our episodes recorded and filmed on-site at the JP Morgan Healthcare Conference, Nima Farzan, CEO of Latigo Biotherapeutics, shares his company's mission to change the pain management paradigm by way of novel, non-o...
•
Episode 246
•
43:32
BoB@JPM: Kasper Roet, Ph.D., QurAlis
Dr. Kasper Roet's hands-on work at the Dutch Brain Bank informed his leadership at the biotech QurAlis, where three clinical programs targeting specific genetic mechanisms in ALS are now underway. On this episode of the Business of Biotec...
•
Episode 245
•
43:46
BoB@JPM: Rick Modi, Affinia Therapeutics
The latest in our series of Business of Biotech podcasts recorded in-person at JPM in San Francisco features an inspiring conversation with Affinia Therapeutics CEO Rick Modi. Modi shares on how his upbringing in Kenya shaped his adversity-embr...
•
Episode 244
•
52:20
BoB@JPM: Owen Hughes & Brad Sitko, XOMA Royalty
On this episode of the Business of Biotech, recorded on-site at the 2025 JP Morgan Healthcare Conference, we explore a new approach to biotech financing with XOMA Royalty's Owen Hughes and Brad Sitko. The CEO and CIO, respectively, share an inn...
•
Episode 243
•
56:27
BoB@JPM: Tom Chalberg, Ph.D., Genascence
Recorded in-person at the JP Morgan Healthcare Conference in San Franscisco, this episode finds Matt Pillar and Ben Comer exploring the evolution of gene therapy with Dr. Tom Chalberg, Founder, Chairman, & CEO at Genascence. We discuss ATMP...
•
48:00
BoB@JPM: Ran Zheng, Landmark Bio
Ran Zhang was hire number one at Landmark Bio back in 2021. Today, she's CEO of the 70+ employee cell and gene therapy manufacturer. We caught up with her and Life Science Leader chief editor Ben Comer at the JP Morgan Healthcare Conference in ...
•
Episode 241
•
37:00
BoB@JPM: Peter Anastasiou, Capsida Biotherapeutics
From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, discusses his journey from big pharma to biotech and the challenges he's faces on the leading edge of first-gneration gene therapies. A...
•
Episode 240
•
45:07